Singapore-Japan Fast Track Pitch Event

 ブラック ジャック 賭け 方Partnering to Accelerate Oncology Solutions 2:Opportunities for Advancement in Vision Care Innovation 3:Medtech Innovation Opportunities in Orthopedic Trauma and Digital Endoscopic Instruments(Japan)

Message from Leadership

Sharon Chan, Head of Johnson & Johnson Innovation – JLABS (JLABS), Asia Pacific

A great idea can come from anywhere. Our mission is to unlock the potential of life science innovation no matter where it originates. Johnson & Johnson Innovation teams aim to solve the world’s toughest health challenges and drive scientific breakthroughs that improve health for everyone, everywhere. We know that a great idea can come from anywhere and we are proud of our strong track record of cultivating innovation and pairing our deep internal know-how with some of the most promising external innovation from around the globe.

Johnson & Johnson's Challenge

ブラック ジャック 賭け 方 Partnering to Accelerate Oncology Solutions
Challenges Worldwide, cancer cases and mortality are expected to increase significantly due to aging and increasing populations, with over half of new diagnoses already occurring in Asia. Thanks to scientific advances and new collaborations, there's reason for hope —and the Janssen Pharmaceutical Companies of Johnson & Johnson are at the forefront of this crucial work. To advance the next generation of innovations, Janssen is seeking to partner with companies with scientific assets under development ((1 year to IND or later stage) in accelerating science and treatments to address hematologic malignancies, including B-cell malignancies, plasma cell malignancies, and myeloid malignancies, as well as solid tumours, such as prostate cancer, non-small cell lung cancer, bladder cancer anブラック ジャック 賭け 方olorectal cancer.
Collaboration Needs Scientific assets under development ((1 year to IND or later stage) in accelerating science and treatments to address hematologic malignancies, including B-cell malignancies, plasma cell malignancies, and myeloid malignancies, as well as solid tumours, such as prostate cancer, non-small cell lung cancer, bladder cancer anブラック ジャック 賭け 方olorectal cancer.
2: Opportunities for Advancement in Vision Care Innovation
Challenges (1) Contact lens
Johnson & Johnson Vision is looking to identify technologies for the next generation of Contact Lenses to advance standards of eye care from Pediatric to Aging Eyes. We are looking for R&ブラック ジャック 賭け 方ollaboration and product/service co-development opportunities to improve quality of vision, comfort and ocular health. Areas of specific interest include (among others):
  • Novel presbyopia solutions for improved range of vision
  • Presbyopia patient screening and fitting tools to improve multifocal lens fitting success and patient experience
  • Light management approaches to improve vision and ocular health
  • Contact lens material science
  • Approaches to reducing the feeling of ocular dryness
  • Technologies to improve manufacturing efficiency and sustainability
(2) Cataracts
A cataract is the clouding of the crystaline lens in the eye, which can lead to vision impairment and potentially blindness. Cataracts remains the world’s leading cause of reversible blindness. Cataract surgery is the world’s most widely performed surgery with high success rates in restoring vision and enhancing quality of life. However, opportunities remain for improvements in the precision of refractive outcomes, visual quality and range of vision (near to distance) as demands on the visual system increase across age groups and patients desire to be spectacle independent. Johnson & Johnson Vision is seeking opportunities for R&ブラック ジャック 賭け 方ollaboration and product/service co-development in the areas of cataract anブラック ジャック 賭け 方orneal refractive surgery.
(3) Ocular Drug delivery
Ocular drugs are commonly delivered via eye drops, which many patients finブラック ジャック 賭け 方hallenging to use and are often associated with poor compliance. Johnson & Johnson Vision is interested in opportunities for R&ブラック ジャック 賭け 方ollaboration and product/service co-development for ocular drug delivery technologies with the potential to improve patient outcomes.
Johnson & Johnson Vision is looking for R&ブラック ジャック 賭け 方ollaboration or co-development opportunities for product / solutions for ocular drug delivery technologies for
  • anterior and posterior segment diseases and ocular health.
  • Improve patient outcomes, ease of use/insertion
  • Prolonged duration of effect / release, improveブラック ジャック 賭け 方ompliance / efficiency.
(4) Myopia Management in Pediatric Eyes
According to the WHO, 50% of the world's population will be myopic by 2050. Johnson & Johnson Vision is looking for R&ブラック ジャック 賭け 方ollaboration or co-development opportunities for potential treatments for myopia progression, predicative tools for identifying children at high risk of progression and tools for parents to monitor myopic progression.
According to the World Health Organization (WHO), 50% of the world's population will be myopic by 2050. 1 billion people will have high myopia (<-5.00D) and a 70% risk of visual impairment at a later age in life. The problem is most severe in Asia, where the prevalence of myopia in those aged 18 years is 80% in several countries.
Johnson & Johnson Vision is looking for R&ブラック ジャック 賭け 方ollaboration or co-development opportunities for product / service / solutions for Myopia management,
Myopia Management innovation areas of interest include:
  • Treatments for preventing onset, slowing and or stopping pediatric myopia progression
  • Predicative tools for identifying children at high risk of progression
  • Monitoring tools for parents to monitor myopic progression
Collaboration Needs (1) Contact lens
We are looking for the following:
  • Novel presbyopia solutions for improved range of vision
  • Presbyopia patient screening and fitting tools to improve multifocal lens fitting success and patient experience
  • Light management approaches to improve vision and ocular health
  • Contact lens material science
  • Approaches to reducing the feeling of ocular dryness
  • Technologies to improve manufacturing efficiency and sustainability
(2) Cataracts
We have an interest in:
  • Intraocular lenses (IOL’s) for extending range and quality of vision, accommodation and adjustability
  • Novel refractive surgery technologies
  • Solutions for streamlining cataract and refractive surgical workflows to improve OR efficiency and patient outcomes
(3) Ocular Drug delivery
We are looking for technologies related to:
  • Anterior and posterior segment diseases and ocular health.
  • Improve patient outcomes, ease of use/insertion
  • Prolonged duration of effect / release, improveブラック ジャック 賭け 方ompliance / efficiency
(4) Myopia Management in Pediatric Eyes
Myopia Management innovation areas of interest include:
  • Treatments for preventing onset, slowing and or stopping pediatric myopia progression
  • Predicative tools for identifying children at high risk of progression
  • Monitoring tools for parents to monitor myopic progression
Opportunity We are looking for R&ブラック ジャック 賭け 方ollaboration and product/service co-development opportunities to improve quality of vision, comfort and ocular health across various potential solutions.
3: Medtech Innovation Opportunities in Orthopedic Trauma and Digital Endoscopic Instruments (Japan)
Challenges (1) Orthopedic Trauma The surgical episode of care can be inefficient and unpredictable for surgeons, care teams, and patients. Common unmet needs could include:
  • Ability to effectively engage patients before and after surgery without adding manual, burdensome processes
  • Improving operational collaboration and planning associated with care team communication, scheduling, backlogs, and workflow
  • High variability of surgical outcomes as a result of lacking data, emphasizing training disparities and resource inequalities
  • Lack of ability to objectively measure patient progress post-operatively and inform care accordingly
(2) Endoscopic Surgery, Japan: Recently in Japan the number of surgeons has decreased due to a variety of factors. Enhanced efficiency and standardization could be essential to helping bring potential surgeons into the OR. IT and AI solutions could help fill the knowledge gap between skilled surgeons and others. Robotic surgery may be one such solution, but complete solutions are still under development. To help bridge this gap, we are seeking to introduce innovative new digital technologies to current Endoscopic surgical procedures
Collaboration Needs
  • Technologies or new processes that improve the patient journey end-to-end and address aforementioned unmet needs in orthopedic trauma care.
  • Technologies or new processes that digitize endoscopic surgery anブラック ジャック 賭け 方an address how IT can be utilized in each phase, including:
    • Education
    • Preoperative (Preparation, Planning, Simulation etc)
    • Intraoperative (Navigation, New technique, Measure, Recording etc)
    • Postoperative (Analyse how it used and outcome, store it as big data and AI for next operation etc)
Opportunity
  • Mentorship from The Johnson and Johnson Family of Companies (Johnson and Johnson) around further development of product/services, including market research
  • Opportunity to be considered for R&ブラック ジャック 賭け 方ollaborations anブラック ジャック 賭け 方ommercial partnerships
  • Investment funding opportunities

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. Every day, our more than 140,000 employees across the world are blending heart, science and ingenuity to profoundly change the trajectory of health for humanity.